ABVC BioPharma (NASDAQ:ABVC – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, FiscalAI reports.
ABVC BioPharma Price Performance
Shares of ABVC BioPharma stock opened at $1.09 on Monday. ABVC BioPharma has a 52 week low of $0.88 and a 52 week high of $5.48. The business’s fifty day simple moving average is $1.20 and its 200-day simple moving average is $1.85. The firm has a market cap of $27.73 million, a PE ratio of -2.73 and a beta of 0.42.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings raised ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.
Hedge Funds Weigh In On ABVC BioPharma
Several large investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in shares of ABVC BioPharma by 5.8% in the 2nd quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock valued at $246,000 after purchasing an additional 6,017 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of ABVC BioPharma in the 3rd quarter valued at $48,000. Finally, Millennium Management LLC acquired a new position in shares of ABVC BioPharma in the 3rd quarter valued at $60,000. Institutional investors and hedge funds own 11.38% of the company’s stock.
About ABVC BioPharma
ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.
The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.
Further Reading
- Five stocks we like better than ABVC BioPharma
- As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
